Letters to the Editor

Back to the Ground

To the Editor:

The absence of any favorable effects of early high-dose recombinant human erythropoietin (rEpo) in acute ischemic stroke reported by the EPO Stroke Trial Group is highly remarkable.1 The findings that rEpo was associated with an overall increased risk of death and of further serious complications (intracerebral hemorrhage, brain edema, thromboembolic events) when combined with recombinant tissue plasminogen activator need to be critically considered in the context of 2 other recent clinical studies on the use of rEpo or darbepoetin-α (a higher glycosylated Epo derivative) aimed at brain or cardiovascular protection. In adults with diabetes, chronic kidney disease, and moderate anemia, darbepoetin-α did not reduce the risk of death or cardiovascular events and was even associated with a higher rate of stroke.2 In very immature preterm infants with a gestational age <26 weeks that received early high-dose rEpo, the rates of severe intraventricular hemorrhage were rather increased, although not statistically significant.3

In these studies, which were conducted with different specific aims, complications emerged that can be attributed to disturbed endothelial functions of immature, vulnerable, or damaged vessels. This notion is supported by experimental data. Analysis of developing mice provide evidence for Epo action on endothelial cells, because ablation of the genes coding for Epo or its receptor results in severe angiogenic defects.4 rEpo protects endothelial cells against apoptosis and stabilizes vascular integrity.5 However, rEpo enhances the expression of tissue factor in the extracellular matrix of endothelial cells, resulting in an increased platelet adherence to injured endothelium.6 Moreover, rEpo leads to excessive neointima formation in injured carotid arteries, likely to increase the risk of vascular stenosis.7 Genetic variations in the Epo gene may additionally predispose to increased severity of diabetic retinopathy.8

Thus, the Epo/Epo receptor biology on endothelial cells needs to be further elucidated not only with regard to tissue protection. Patients with cancer, in whom rEpo may promote tumor growth, angiogenesis, and modulate sensitivity of chemotherapeutic drugs,9 will also benefit from this research.

Disclosures

None.

References


© 2010 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org

(Stroke. 2010;41:e166.)

DOI: 10.1161/STROKEAHA.109.575274
Back to the Ground
Christof Dame

Stroke. 2010;41:e166; originally published online February 4, 2010;
doi: 10.1161/STROKEAHA.109.575274
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/41/3/e166

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/